Palantir's Maven AI Earns Pentagon "Program of Record" Status, Reshaping Military AI Strategy 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
Genel Energy Reports FY25 Net Loss Below Fears, EBITDAX Beats Forecasts 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity 
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
Paraguay Central Bank Holds Interest Rate at 5.5% Amid Slowing Growth 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem 
United Airlines Cuts Flights 5% Amid Soaring Fuel Costs From Iran War 
U.S.-Iran War Escalates: Marines Deploy, Strait of Hormuz Closure Drives Global Oil Crisis 
Japan's Parliament Backs Dovish BOJ Board Members, Raising Questions on Rate Hike Path 
FCC Approves $3.54B Nexstar-Tegna Merger, Waiving Broadcast Ownership Cap 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
